MedTrace Logo

Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer

NCT00102375 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 900

Last updated 2006-08-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether the triple combination of Carboplatin, Paclitaxel and Topotecan has a superior clinical outcome in the treatment of ovarian cancer compared with the combination of Carboplatin and Paclitaxel.

Conditions

Interventions

DRUG

Topotecan

Sponsors & Collaborators

  • AGO Study Group

    lead OTHER

Principal Investigators

  • Jacobus Pfisterer, Prof. Dr. · AGO Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Completion
2004-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00102375 on ClinicalTrials.gov